share_log

SVB Leerink Downgrades Calithera Biosciences to Market Perform, Lowers Price Target to $2

Benzinga Real-time News ·  Nov 15, 2022 04:08

SVB Leerink analyst Jonathan Chang downgrades Calithera Biosciences (NASDAQ:CALA) from Outperform to Market Perform and lowers the price target from $18 to $2.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment